Catalyst-Free One-Pot Synthesis of Densely Substituted Pyrazole-Pyrazines as Anti-Colorectal Cancer Agents. 2020

Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, Chongqing University of Arts and Sciences, Chongqing, 402160, China.

The first catalyst-free post-Ugi cascade methodology was developed for expeditious access to structurally diverse and complex pyrazole-pyrazines in one-pot. This novel cascade reaction features an intramolecular N2-arylation of pyrazoles with allenes at the C-β position of triple bond. Screening in the colorectal cancer cell lines HCT116 and SW620 validated the feasibility of the methodology for generating bioactive compounds. The lead compound 7h which is active against HCT116 and SW620 with IC50 of 1.3 and 1.8 µM, respectively, can be synthesized and purified in a gram process synthetic scale in 7 hours. The mechanical studies indicated that compound 7h can induce cell cycle arrest in the G2/M phase and inhibit proliferation and viability in human colon cancer cells. Overall, compound 7h is represented as a promising starting point for the development of new anti-colorectal cancer drugs.

UI MeSH Term Description Entries
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
January 2024, RSC medicinal chemistry,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
January 2013, Beilstein journal of organic chemistry,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
January 2020, Drug design, development and therapy,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
May 2017, ACS combinatorial science,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
January 2013, Acta poloniae pharmaceutica,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
December 2017, Acta chimica Slovenica,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
November 2005, European journal of medicinal chemistry,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
February 2011, Molecular diversity,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
August 2013, Molecular diversity,
Jia Xu, and Hong-Bo Tan, and Ya-Jun Zhang, and Dian-Yong Tang, and Fenghuang Zhan, and Hong-Yu Li, and Zhong-Zhu Chen, and Zhi-Gang Xu
May 2017, Chemistry Central journal,
Copied contents to your clipboard!